Publications in collaboration with researchers from University of Münster (15)

2021

  1. Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data

    The Journal of molecular diagnostics : JMD, Vol. 23, Núm. 3, pp. 347-357

2019

  1. Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID

    Nature Communications, Vol. 10, Núm. 1

  2. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

    Haematologica, Vol. 104, Núm. 5, pp. 929-936

2018

  1. Lmo2 expression defines tumor cell identity during T-cell leukemogenesis

    EMBO Journal, Vol. 37, Núm. 14

  2. Loss of Pax5 exploits sca1-BCR-ABLp190 susceptibility to confer the metabolic shift essential for pB-ALL

    Cancer Research, Vol. 78, Núm. 10, pp. 2669-2679

2015

  1. Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility

    Cancer Discovery, Vol. 5, Núm. 12, pp. 1328-1343

2013

  1. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma

    Journal of Clinical Oncology, Vol. 31, Núm. 4, pp. 448-455

2011

  1. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial

    British Journal of Haematology, Vol. 153, Núm. 2, pp. 212-221

  2. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma

    European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384

  3. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma

    Haematologica, Vol. 96, Núm. 2, pp. 238-244

  4. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study

    European Journal of Haematology, Vol. 86, Núm. 1, pp. 23-31

2010

  1. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

    Blood, Vol. 116, Núm. 19, pp. 3743-3750

2008

  1. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

    New England Journal of Medicine, Vol. 359, Núm. 9, pp. 906-917

2006

  1. Near-tetraploid acute myeloid leukemias: An EGIL retrospective study of 25 cases [2]

    Leukemia

2004

  1. Testosterone replacement therapy: Current trends and future directions

    Human Reproduction Update, Vol. 10, Núm. 5, pp. 409-419